Book your personalized demo today!
South Hall Booth 2565
Learn how patients and providers benefit from Volpara's health technologies
Volpara Solutions is launching a new version of VolparaLive!. The VolparaLive! system automatically analyzes patient positioning and compression and provides real-time feedback to Technologists. It is mammography’s first real-time decision support system available at the point of care. Designed to help technologists acquire consistent, high quality mammograms, VolparaLive! puts data in the technologists’ hands before the patient leaves the room. This helps optimize productivity, reduce costs through the reduction of retakes, and increase staff effectiveness.
VolparaEnterprise software delivers key performance indicators for hundreds of performance and quality metrics, including patient positioning, compression, and equipment utilization. The software provides continuous quality assurance and performance monitoring through dynamic, interactive dashboards. Updated with every mammography or tomosynthesis (3D mammography) exam, ConstantQuality metrics may help facilities comply with the FDA’s new EQUIP inspection program.
Volpara will also showcase VolparaEnterprise DDP software. The VolparaEnterprise Clinical Applications software package offers access to VolparaDensity, VolparaDose and VolparaPressure producing a Volpara Scorecard for every patient.
Volpara RSNA booth talks
Professor Jack Cuzick, John Snow Professor of Epidemiology, Director, Wolfson Institute of Preventive Medicine, Head, Centre for Cancer Prevention, Queen Mary
Sunday, November 25 at 2:30 PM
Monday, November 26 at 11:00 AM
Mammographically assessed breast density is the strongest known risk factor for breast cancer on a population basis and can be measured in several ways. The most widely used BI-RADS uses a four-category visual assessment. However, this system is subjective and focusses on areas where density could mask identification of a tumor, and less on risk assessment. More recently automated volumetric measurements have been developed based on the degree of opacity in each pixel of the mammogram to assess the depth of dense tissue in that pixel, thus arriving at a measure of the total volume of breast tissue which is dense. This can be used either as an absolute measurement or a percent volumetric density. Such measures may be more informative as the volume of tissue is likely to be the more critical factor for increased risk. These measures are objective, reproducible and are automatically generated without radiologist intervention.
In this talk I review several large cohort studies demonstrating not only the univariate strength of mammographic density, but also its near independence and added value to both questionnaire-based risk factors and single nucleotide polymorphism (SNP) panels. The value of changes in breast density after endocrine therapy as markers of treatment effectiveness is also briefly reviewed.
Professor Jack Cuzick is a director of Wolfson Institute of Preventive Medicine in London. He is also head of Centre for Cancer Prevention and John Snow Professor of Epidemiology at Queen Mary, University of London. He holds a PhD in Mathematics and has previously worked at Oxford University and Columbia University, New York. His current interests are in cancer epidemiology and clinical trials, with special interest in prevention and screening. He is currently Chairman of the International Breast Cancer Intervention Study (IBIS) Steering Group and the ATAC trial. He has worked extensively in breast cancer research and was the first to report the effect of tamoxifen on contralateral tumors as an indicator of its potential chemopreventive role and has demonstrated that a change in mammographic breast density on endocrine treatment is a biomarker for its effectiveness. He is the statistician for several major breast cancer trials and maintains an active interest in developing new statistical methodology, especially in adjustments for non-compliance and cross-over, and multi-arm clinical trials. In 2016 he was awarded a CBE (Commander of the order of the British Empire) by the Queen for services to cancer prevention and screening. He is a Fellow of the Royal Society, the Academy of Medical Sciences, the Royal Statistical Society, the Institute of Mathematical Statistics and an Honorary Fellow of the Royal College of Physicians. In 2007 and subsequently, he was chosen by Thompson Scientific as one of the twelve hottest researchers in all of science. He was awarded the AACR Cancer Prevention Prize in 2012, the CRUK Translational Cancer Research Prize team prize in 2014, Robert Sutherland Award for Excellence in Translational Research (Australia) and the ACS Medal of Honor in 2015. He is the author of more than 600 peer-reviewed papers and has published in all the major medical journals.
Professor Sir Mike Brady, Professor of Oncological Imaging, University of Oxford
Tuesday, November 27 at 11:00 AM
Wednesday, November 28 at Noon
Artificial Intelligence (AI) and Machine Learning (ML) are currently, and rightly, hot topics, though they are not the same. We first outline what is meant by AI, and especially ML. These technologies have been developing rapidly over the past 30 years, and so has mammography. Still, the applications of AI and ML to mammography have to date been remarkably narrow but that is changing.
Professor Sir Mike Brady, a founding director of Volpara Health Technologies, is currently Professor of Oncological Imaging at the University of Oxford, having recently retired after 25 years as Professor of Information Engineering. He served for 20 years as a non-executive director and deputy chairman of the FTSE 250 company Oxford Instruments plc and for 10 years as a non-executive director of AEA Technology plc.
Mike is founding director of Perspectum Diagnostics, which performs liver image analysis by MRI, and Mirada Medical Limited, which develops medical image analysis software and is installed in almost 2000 hospitals worldwide; ScreenPoint, which develops machine learning methods for computer-aided diagnosis in mammography; Optellum, which develops software to classify lung nodules in CT; and Guidance Navigation Holdings, which develops systems to aid navigation of vessels near large structures.
Mike is the author of over 750 articles and 35 patents in computer vision, robotics, medical image analysis and artificial intelligence, and the author or editor of 10 reference books. He is based in Oxford, UK.
JoAnn Pushkin, Executive Director, DenseBreast-info.org
Monday, November 26 at Noon
Tuesday, November 27 at 2:00 PM
35 states now require some level of density notification, but they vary. It is important to understand what level of information is being provided to, and how it is being interpreted by, patients. Is there a national reporting standard on the horizon and will it solve the issue of variations in the laws? Learn what educational tools are available for patients and health providers in both the U.S. and Europe on the topic.
JoAnn Pushkin is executive director of educational website DenseBreast-info.org. The website is the only medically-sourced website developed for both patients and health providers and was cited in a recent comparative study to be the most up-to-date and comprehensive on the topic. Ms. Pushkin is also an advocate, author and speaker and her story of a missed cancer served as inspiration for New York State's Breast Density Inform law. On the federal level, Ms. Pushkin led the efforts for both the introduction of the Federal Breast Density and Mammography Reporting Act, as well as the FDA’s Mammography Quality Standards Act regulatory reporting amendment consideration.
Amy Chatten, MPH, Executive Director, Mammography Educators
Monday, November 26 at 2:30 PM
Wednesday, November 28 at 11:00 AM
Clinical image quality directly affects the ability to detect early breast cancers. Studies have shown that the utilization of upgraded standardized positioning techniques, appropriate for FFDM and DBT, which can be analyzed objectively, set a higher and more reasonable expectation regarding positioning standards and clinical image analysis. Mammography Educators and Volpara Solutions have collaborated to create methods of positioning training and computerized image analysis that improve image quality and will ultimately lead to the earlier detection of breast cancer.
Amy Chatten is the co-founder and Executive Director of Mammography Educators. She has her Master’s in Public Health with a focus on maternal and child health. Amy worked as the Manager of Breast Imaging at the University of California San Diego Health System for over five years and has experience leading programs for 16 years. Her expertise is in clinical operations, program planning and analysis.
Ms. Chatten was selected as the Quality Improvement Leader for the Department of Radiology at the University of California San Diego. She spearheaded the effort to achieve the prestigious American College of Radiology Breast Imaging Center of Excellence designation within her first year and a half as Manager of the department. Amy has almost two decades of experience in program planning and analysis, as well as training in Six Sigma and Kaizen for performance improvement strategies. She is focused on providing a superior patient experience with an emphasis on high quality care and patient safety.
Schedule a Demo to See How Volpara’s Technology Can Help You
Volpara offers high-quality breast cancer screening solutions based on objective measurements of breast density, compression, and radiation dose. Please contact us to schedule a demo at RSNA and see what Volpara can do for you.